Additional Information
This workshop will focus on the key preclinical experimental validation package components that de-risk and provide rigorous rationale for the pursuit of novel targets with minimal side effects and a reduced potential abuse/addiction liability into drug discovery campaigns.
The focus will be on the stage appropriate data required to justify further preclinical and clinical therapeutics development activities across the translational spectrum. Several perspectives will be presented including industry, academia, and venture capital.